Financial Snapshot

Revenue
$210.4M
TTM
Gross Margin
94.72%
TTM
Net Earnings
$15.50M
TTM
Current Assets
$101.4M
Q3 2024
Current Liabilities
$81.01M
Q3 2024
Current Ratio
125.15%
Q3 2024
Total Assets
$104.2M
Q3 2024
Total Liabilities
$81.37M
Q3 2024
Book Value
$22.83M
Q3 2024
Cash
P/E
14.13
Nov 29, 2024 EST
Free Cash Flow
$5.276M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2021 2020 2017 2016 2011 2010 1999 1998
Revenue $16.69M $4.340M $2.520M $330.0K $620.0K $1.360M $1.260M $1.320M $0.00
YoY Change 72.22% -46.77% 7.94%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2021 2020 2017 2016 2011 2010 1999 1998
Revenue $16.69M $4.340M $2.520M $330.0K $620.0K $1.360M $1.260M $1.320M $0.00
Cost Of Revenue $1.262M $1.520M $1.270M $150.0K $390.0K $310.0K $230.0K $740.0K $0.00
Gross Profit $15.42M $2.820M $1.250M $180.0K $220.0K $1.050M $1.030M $580.0K $0.00
Gross Profit Margin 92.44% 64.98% 49.6% 54.55% 35.48% 77.21% 81.75% 43.94%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2021 2020 2017 2016 2011 2010 1999 1998
Selling, General & Admin $22.03M $3.850M $2.860M $5.010M $3.350M $1.330M $1.200M $4.900M $40.00K
YoY Change 34.62% 49.55% 10.83% 12150.0%
% of Gross Profit 142.81% 136.52% 228.8% 2783.33% 1522.73% 126.67% 116.5% 844.83%
Research & Development $327.3K $120.0K
YoY Change
% of Gross Profit 2.12% 4.26%
Depreciation & Amortization $229.0K $280.0K $240.0K $200.0K $160.0K $250.0K $220.0K $920.0K $0.00
YoY Change 16.67% 25.0% 13.64%
% of Gross Profit 1.48% 9.93% 19.2% 111.11% 72.73% 23.81% 21.36% 158.62%
Operating Expenses $22.58M $4.250M $3.090M $5.010M $3.350M $1.580M $1.420M $8.520M $870.0K
YoY Change 37.54% 49.55% 11.27% 879.31%
Operating Profit -$7.159M -$1.430M -$1.840M -$4.830M -$3.130M -$530.0K -$390.0K -$7.940M -$870.0K
YoY Change -22.28% 54.31% 35.9% 812.64%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2021 2020 2017 2016 2011 2010 1999 1998
Interest Expense -$700.3K -$530.0K -$30.00K -$50.00K $150.0K -$200.0K -$30.00K
YoY Change -40.0% 566.67%
% of Operating Profit
Other Income/Expense, Net -$3.690K -$610.0K $0.00 $0.00 $10.00K $0.00 -$200.0K
YoY Change -100.0% -100.0%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2021 2020 2017 2016 2011 2010 1999 1998
Pretax Income -$7.863M -$1.410M -$2.370M -$4.860M -$3.200M -$530.0K -$240.0K -$8.140M -$1.100M
YoY Change -40.51% 51.88% 120.83% 640.0%
Income Tax $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$7.863M -$1.370M -$2.390M -$4.840M -$3.200M -$530.0K -$240.0K -$8.140M -$1.100M
YoY Change -42.68% 51.25% 120.83% 640.0%
Net Earnings / Revenue -47.12% -31.57% -94.84% -1466.67% -516.13% -38.97% -19.05% -616.67%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.57 -$0.15 -$0.26 -$1.15 -$0.96 -$26.50 -$12.00 -$203.50 -$3.425B

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2021 2020 2017 2016 2011 2010 1999 1998
Cash & Short-Term Investments $239.4K $340.0K $100.0K $50.00K $180.0K $30.00K $30.00K $40.00K $0.00
YoY Change 240.0% -72.22% 0.0%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $329.2K $40.00K $170.0K $10.00K $10.00K $1.910M $0.00
YoY Change -76.47% 0.0%
Inventory $658.7K $320.0K $570.0K $150.0K $90.00K $450.0K $0.00
Prepaid Expenses
Receivables $11.37M $300.0K $10.00K $20.00K $30.00K $40.00K $40.00K $130.0K $0.00
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00 $20.00K $10.00K $0.00 $0.00
Total Short-Term Assets $12.60M $1.000M $850.0K $230.0K $320.0K $80.00K $80.00K $2.520M $0.00
YoY Change 17.65% -28.13% 0.0%
Property, Plant & Equipment $1.369M $1.280M $1.350M $1.680M $1.780M $1.940M $2.210M $440.0K $0.00
YoY Change -5.19% -5.62% -12.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $60.00K $0.00
YoY Change
Other Assets $0.00 $0.00 $10.00K $100.0K $1.460M $400.0K $10.00K $0.00
YoY Change -90.0% 265.0%
Total Long-Term Assets $1.961M $1.740M $1.820M $2.160M $2.910M $3.390M $2.620M $3.550M $0.00
YoY Change -4.4% -25.77% 29.39%
Total Assets $14.56M $2.740M $2.670M $2.390M $3.230M $3.470M $2.700M $6.070M $0.00
YoY Change
Accounts Payable $1.031M $810.0K $610.0K $560.0K $1.310M $4.080M $50.00K
YoY Change 32.79% -57.25% 8060.0%
Accrued Expenses $1.698M $2.300M $1.880M $100.0K $60.00K
YoY Change 22.34% 66.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $3.600M $230.0K $460.0K $400.0K $0.00 $0.00 $1.230M $220.0K
YoY Change 1465.22% 15.0% 459.09%
Long-Term Debt Due $4.455M $30.00K $3.900M $50.00K $530.0K $20.00K $0.00
YoY Change -99.23% -90.57%
Total Short-Term Liabilities $15.26M $6.730M $6.800M $1.100M $2.260M $5.570M $370.0K
YoY Change -1.03% -51.33% 1405.41%
Long-Term Debt $268.9K $1.410M $1.500M $500.0K $0.00 $0.00 $0.00 $2.390M $420.0K
YoY Change -6.0% 469.05%
Other Long-Term Liabilities $14.85K $0.00 $0.00
YoY Change
Total Long-Term Liabilities $283.8K $1.410M $1.500M $500.0K $0.00 $0.00 $0.00 $2.390M $420.0K
YoY Change -6.0% 469.05%
Total Liabilities $15.54M $8.300M $8.470M $1.570M $2.250M $7.970M $790.0K
YoY Change -2.01% -30.22% 908.86%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2021 2020 2017 2016 2011 2010 1999 1998
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $219.1 Million

About BIOSTEM TECHNOLOGIES

BioStem Technologies, Inc. engages in the provision of regenerative medicine and anti-aging solutions. The company is headquartered in Pompano Beach, Florida. The company went IPO on 2001-07-11. Leveraging its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. Its products include VENDAJE, VENDAJE AC, VENDAJE OPTIC and AmnioWrap2. VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. VENDAJE is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE AC is a thicker structural tissue allograft composed of the amnion and chorion layer of the placental membrane. VENDAJE AC is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE OPTIC is a structural tissue allograft composed of the amnion layer of the placental membrane. AmnioWrap is a placental-based allografts comprised of unseparated amnion and chorion membranes, including the intact intermediate layer.

Industry: Biological Products, (No Diagnostic Substances) Peers: Athira Pharma, Inc. Citius Pharmaceuticals, Inc. ELI LILLY & Co Eton Pharmaceuticals, Inc. ORAMED PHARMACEUTICALS INC. MARIMED INC. NGM BIOPHARMACEUTICALS INC REVIVA PHARMACEUTICALS HOLDINGS, INC.